ID
38162
Descripción
Study ID: 105-123 Clinical Study ID: 105-123 Study Title: Lamotrigine as add-on therapy in patients with clinical diagnosis of a Lennox-Gastaut syndrome (severe generalised epilepsy of childhood onset.) A multicentre, double-blind, placebo controlled parallel group study Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Lamotrigine Study Indication: Seizures
Palabras clave
Versiones (1)
- 23/9/19 23/9/19 -
Titular de derechos de autor
GlaxoSmithKline
Subido en
23 de septiembre de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Lamotrigine as add-on therapy in patients with a clinical diagnosis of a Lennox-Gastaut syndrome (105-123)
Comment Log; Investigator's Statement
- StudyEvent: ODM
Descripción
Comment Log
Alias
- UMLS CUI-1
- C0947611
Descripción
Investigator's Statement
Alias
- UMLS CUI-1
- C0008961
- UMLS CUI-2
- C1710187
Descripción
I confirm that I have carefully examined all entries on the Case Report Forms for this patient. All Information entered by myself or my colleagues is, to the best of my knowledge, correct as of the date below.
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C1519316
- UMLS CUI [1,2]
- C1521895
Descripción
Principal Investigator's Name
Tipo de datos
text
Alias
- UMLS CUI [1]
- C2826892
Descripción
Signature Date
Tipo de datos
date
Alias
- UMLS CUI [1,1]
- C2346576
- UMLS CUI [1,2]
- C0011008
Similar models
Comment Log; Investigator's Statement
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C1710187 (UMLS CUI-2)
C1521895 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
Sin comentarios